Go to the list of all blogs
Scott Bell's Avatar
published in Blogs
Oct 19, 2026
TickeronGET DAILY SIGNALS
Why Is Glass House Brands (GLAS) Stock Down -40.44% Today?

Why Is Glass House Brands (GLAS) Stock Down -40.44% Today?

Key Takeaways

  • GLAS shares plunged roughly 40% intraday after the company pre-announced third-quarter results.
  • The primary catalyst was sharp margin compression, with average selling price falling to $150 per pound from $211 per pound in the prior quarter.
  • Record production and revenue were overshadowed by a deteriorating California wholesale cannabis pricing environment.
  • A surprise board resignation added a layer of governance uncertainty to the selloff.
  • Traders are watching for price stabilization and the company's next scheduled earnings report.

Opening Summary

Glass House Brands Inc. (GLAS), a vertically integrated California-focused cannabis cultivator and consumer packaged goods company, saw its shares crater on Monday after releasing preliminary third-quarter financial results. The stock traded down roughly 40.44% to approximately $1.90 in morning trading, compared with a prior-session close of $3.19 on Friday, October 16. The move confirmed a steep decline driven by sharply weaker wholesale pricing and gross-margin compression, despite headline revenue and production figures that came in ahead of expectations.

Q3 Preliminary Results: Pricing Pressure Hits Margins

The selloff traces directly to the company's pre-announcement of unaudited results for the quarter ended September 30, 2026. Glass House reported revenue of $56.8 million, up 21% sequentially from $47.0 million and more than double the $26.2 million reported a year earlier, and record biomass production of approximately 317,000 pounds. Yet the market focused on the deterioration in unit economics: average wholesale selling price dropped to $150 per pound from $211 per pound in the second quarter, a decline of roughly 29%, while gross margin narrowed to 26% from 34%.

The result was gross profit of $14.9 million, essentially flat quarter over quarter despite materially higher volume, and operating cash flow that turned slightly negative at -$0.4 million versus +$0.2 million in the prior quarter. Management attributed the compression to a trim-heavy sales mix and seasonal pricing weakness in California. Investors interpreted the data as a sign that volume growth is being absorbed by falling prices rather than converting into improved profitability.

Deteriorating California Wholesale Pricing and Sector Sentiment

Beyond the company's own figures, the move reflects a broader malaise in the California wholesale cannabis market. Pricing has been under sustained pressure as supply remains plentiful, compressing margins across operators even as Glass House continues to lower its cost of production, which fell roughly 10% sequentially to about $110 per pound. The company reaffirmed its full-year 2026 production target of approximately one million pounds and its long-term goal of $95 per pound, but those efficiency gains have not been enough to offset the decline in realized prices.

The share-price reaction also echoes sentiment across the cannabis sector, which has traded with elevated volatility and sensitivity to capital availability and regulatory expectations. As a lower-priced, relatively thinly traded name near its 52-week low, GLAS is prone to outsized percentage moves when selling pressure builds.

Board Departure Adds to Governance Concerns

Compounding the negative reaction, the company disclosed that director John Nichols Jr. resigned from the board, with no reason provided in the announcement. The departure follows a run of recent governance and management changes, including a previously announced CFO retirement and an auditor change, adding an element of uncertainty that weighed on sentiment alongside the weak margin data.

Market Context and Trading Activity

Trading volume was elevated relative to the stock's recent average as investors absorbed the pre-announcement. The decline pushed shares well below their 50-day and 200-day moving averages and toward the lower end of a 52-week range of roughly $3.10 to $13.93. The move diverged from the broader tape and is best understood as a company- and sector-specific repricing rather than a reflection of general equity-market conditions. The stock's low absolute price and concentrated trading profile likely amplified the percentage decline.

What Comes Next for GLAS

Attention now turns to whether management can stabilize realized pricing and demonstrate a credible path to positive cash flow. The company ended the quarter with about $39.7 million in cash and said it has turned off its at-the-market equity program after raising capital earlier in the year, which reduces near-term dilution risk but leaves execution on margin recovery as the key variable. Upcoming earnings and any further commentary on California pricing, the greenhouse optimization program, and the timeline for reaching cash-flow breakeven will be closely watched. Risks include continued wholesale price erosion, financing conditions, and the absence of fresh regulatory catalysts for the cannabis sector.

Trending AI Robots

For traders seeking a data-driven edge across volatile names like GLAS, Tickeron's Trending AI Robots page offers a curated view of its strongest-performing automated strategies. Tickeron hosts hundreds of AI trading bots covering thousands of tickers, but only those delivering standout results under current market conditions are featured in this section. The bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing users to evaluate approaches that fit their own objectives. Explore the Trending AI Robots page to see which strategies are currently leading the market.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: GLAS

Contributor

Scott Bell's AvatarScott Bell|Expert

I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking


GLAS sees MACD Histogram just turned negative

GLAS saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on September 24, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 35 instances where the indicator turned negative. In 32 of the 35 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 50-day moving average for GLAS moved below the 200-day moving average on September 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GLAS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

The Aroon Indicator for GLAS entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 16 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

GLAS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 43 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.139) is normal, around the industry mean (10.234). P/E Ratio (-4.197) is within average values for comparable stocks, (-6.027). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.039) among similar stocks. P/S Ratio (3.880) is also within normal values, averaging (178.797).

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. GLAS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GLAS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.26B. The market cap for tickers in the group ranges from 2.12K to 68.49B. MKGAF holds the highest valuation in this group at 68.49B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -5%. For the same Industry, the average monthly price growth was -7%, and the average quarterly price growth was 9%. RGC experienced the highest price growth at 30%, while SXTC experienced the biggest fall at -56%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was -15%. For the same stocks of the Industry, the average monthly volume growth was 53% and the average quarterly volume growth was -7%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 43
P/E Growth Rating: 54
Price Growth Rating: 58
SMR Rating: 87
Profit Risk Rating: 84
Seasonality Score: 8 (-100 ... +100)
View a ticker or compare two or three
GLAS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsGeneric

Industry
N/A
Address
3645 Long Beach Boulevard
Phone
+1 212 299-7670
Employees
428
Web
https://www.glasshousebrands.com
Interact to see
Advertisement
The Bitwise Solana Staking ETF (BSOL) advanced roughly 18% over the trailing 30 days, closely tracking a sharp rally in Solana (SOL). The move extends a broader recovery, with BSOL up approximately 77% over the past three months from its mid-2026 trough.
MSTY is an actively managed single-stock option income ETF (exchange-traded fund) that writes call options on Strategy (MSTR), formerly MicroStrategy, to generate current income. The portfolio is anchored by U.S. Treasury bills and MSTR option contracts rather than a diversified basket of equities, concentrating exposure in one volatile underlying.
AMDL has surged roughly +64% over the past 30 days, from about $47.59 to $78.10, mirroring a powerful rally in its sole underlying stock, AMD . The fund is a leveraged single-stock ETF (exchange-traded fund) designed to deliver 2x the daily return of AMD, amplifying both gains and losses.
TSMX, a 2x daily leveraged single-stock ETF (exchange-traded fund), rose roughly +19% over the trailing 30 days, rebounding sharply from mid-September lows. The fund seeks 200% of the daily return of TSM (Taiwan Semiconductor Manufacturing), meaning its moves are roughly double the underlying stock's daily swings.
Contracted revenue anchor: A roughly $3.2 billion, seven-year LNG (liquefied natural gas) supply agreement with Puerto Rico has received final approval, providing multi-year cash-flow visibility if execution stays on track. Project pipeline inflection: Upcoming milestones include the Barcarena and PortoCem power plants in Brazil, a potential Gás Sul terminal restart, and optimization of the company's modular "Fast LNG" (FLNG) liquefaction fleet.
AMD (Advanced Micro Devices) designs central processing units (CPUs), graphics processing units (GPUs), and AI accelerators, while LRCX (Lam Research) supplies the wafer-fabrication equipment used to build advanced chips. AMD has delivered strong double-digit revenue growth on AI data-center demand, but its shares trade with elevated expectations that can trigger sharp reactions around earnings.
Origination momentum: Velocity Financial enters 2026 off record annual originations of roughly $2.7 billion (up about 48%), positioning it to keep gaining share in a fragmented investor-loan market. Credit normalization is the central watch item: Nonperforming loans fell toward the 8.5% range of portfolio unpaid principal balance (UPB), but asset quality remains the primary swing factor for earnings.
Turnaround milestone ahead: Management has pointed to reaching cash generation in 2027, making the pace of cost discipline and margin recovery the central question for the stock forecast. Fresh capital supports execution: A recently announced $45.5 million equity financing, with participation from management and a single institutional investor, strengthens the balance sheet as the company funds its transformation.
NFE closed at $5.51, down -6.13% during Tuesday's regular session, extending a slide that has pushed shares near a 52-week low. Primary catalyst: the company disclosed its Fast LNG unit is offline after a gas-turbine mechanical failure, with return to service not expected until Q4.
The central $11 target is the arithmetic mean of four verified analyst price targets, rounded from roughly $10.75. With the stock near $2.06, reaching $11 would require an upside of more than 400%, an extremely large move.
The $23 central target is the rounded arithmetic mean of four verified analyst price targets, which average $23.25. The latest verified price is around $9.57, meaning the target implies roughly 140% upside—a very large move.
NXH closed down -11.17% (-$0.23) to $1.83 on Oct 6, the most recent regular session, extending a steep two-day decline. Selling continued as investors digested the mutual termination of the Fathom Holdings merger and a dilutive $45.5M registered direct offering of ~16.5M shares at $2.76.
AMD is a large-cap designer of CPUs (central processing units) and GPUs (graphics processing units) competing directly with Nvidia in the AI accelerator market, while FORM is a small-cap provider of semiconductor test and measurement equipment, primarily probe cards. AMD's narrative has been driven by multi-billion-dollar hyperscaler deals, while FORM's has been powered by record revenue and sharp margin expansion tied to high-bandwidth memory (HBM) demand.
AMD has surged roughly 200% year to date, crossing a $1 trillion market capitalization on AI data-center demand and a "CPU renaissance" narrative. KLAC has gained about 71% year to date, supported by record process-control revenue and rapid growth in advanced packaging for AI chips.
AMD is a large-cap semiconductor designer riding explosive AI compute demand, while ENTG is a mid-cap supplier of materials and purity solutions that feed the same AI-driven chip cycle. AMD recently crossed a $1 trillion market capitalization on surging data center revenue, whereas ENTG operates at a far smaller scale (roughly $23 billion) with steadier, double-digit growth.
VELO closed Tuesday at $9.57, unchanged (+0.00%) from the prior session, with the move occurring during regular market hours. The flat close marked stabilization after Monday's -14.5% plunge, when shares fell to $9.57 from $11.20 following disclosure of CFO James Suva's departure.
The $8 target used here is a technical, publicly discussed recovery objective — not an analyst consensus — because legacy analyst price targets were set before NFE's restructuring and reverse stock split. New Fortress Energy Inc. ( NFE ) trades near $5.51, so reaching $8 implies a roughly 45% advance.
AVBP plunged -46.98% during Tuesday's regular session, closing at $15.09 versus $28.46, marking its worst single-day decline on record. The catalyst was the Phase 3 FURVENT trial of firmonertinib failing its primary endpoint—progression-free survival—in first-line EGFR exon 20 insertion non-small cell lung cancer.
Upcoming catalyst: The company's next earnings release is estimated for November 6, 2026, which should offer fresh detail on its SKY token holdings, staking rewards, and treasury strategy. Strategic positioning: SDEV is an on-chain holding company providing public-market exposure to the Sky protocol ecosystem, with SKY as its core digital asset and a stated focus on the stablecoin economy.
Different roles in the chip ecosystem: AMAT is a materials-engineering and deposition leader, while KLAC dominates process control, inspection, and yield management. Momentum favors AMAT: AMAT shares have more than doubled this year, while KLAC has recently pulled back roughly 9% in a month on margin and execution concerns.